Department of Otorhinolaryngology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Personalized Medicine, Asthma and Allergy - IRCCS Humanitas Research Hospital - Rozzano (MI), ItalyPersonalized Medicine, Asthma and Allergy - IRCCS Humanitas Research Hospital - Rozzano (MI), Italy.
Laboratory of Allergy and Clinical Immunology Research Unit, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Rhinology. 2023 Jun 1;61(3):194-202. doi: 10.4193/Rhin22.489.
Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with a significant impact on the quality of life (QoL). It is typically characterized by a type 2 inflammatory reaction and by comorbidities such as asthma, allergies and NSAID-Exacerbated Respiratory Disease (N-ERD). Here, the European Forum for Research and Education in Allergy and Airway diseases discusses practical guidelines for patients on biologic treatment. Criteria for the selection of patients who would benefit from biologics were updated. Guidelines are proposed concerning the monitoring of the drug effects that provide recognition of responders to the therapy and, subsequently, the decision about continuation, switching or discontinuation of a biologic. Furthermore, gaps in the current knowledge and unmet needs were discussed.
伴有鼻息肉的慢性鼻-鼻窦炎（CRSwNP）是一种使人虚弱的疾病，对生活质量（QoL）有重大影响。它通常以 2 型炎症反应为特征，并伴有哮喘、过敏和非甾体抗炎药-加重的呼吸道疾病（N-ERD）等合并症。在这里，欧洲过敏和气道疾病研究与教育论坛讨论了生物治疗患者的实用指南。更新了生物制剂治疗获益患者的选择标准。提出了关于药物效果监测的指南，这些指南可识别对治疗有反应的患者，从而决定继续、转换或停止生物制剂治疗。此外，还讨论了当前知识的空白和未满足的需求。
